Generative genomics uses AI to optimize biotech research

At the BIO International Convention, experts discussed the emergence of generative genomics, a field that utilizes artificial intelligence to analyze genetic sequences. This technology aims to identify patterns within DNA and RNA data to discover new medical treatments more efficiently.

Proponents suggest that generative genomics could significantly reduce the time and cost of drug development. Currently, developing a new drug costs an average of $2 billion and can take over a decade. AI integration could potentially shorten these timelines from years to months. Furthermore, the technology may improve clinical trial success rates, which currently stand at approximately 10%.